Clinical Trial Update: The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated palonosetron for preventing gastrointestinal reactions from 3-day highly emetogenic chemotherapy; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Palonosetron (palonosetron)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Cancer | Phase 2 | Status: COMPLETED